Earnings call transcript: Tobii Dynavox’s Q1 2026 revenue surges 15% YoY

Tobii Dynavox reported Q1 2026 revenue of SEK 588 million, up 15% year over year on 11% organic growth, with EBIT rising 56% to SEK 57 million and basic EPS up to 0.33 SEK from 0.23 SEK. Management said weather disrupted U.S. demand in January and February and FX cut reported revenue by 14%, but it expects deferred business to return and reiterated a 20% annual revenue growth target plus a 15%+ EBIT margin goal. The company also highlighted strong cash flow, a proposed 0.5 SEK dividend, continued ERP/IT investment, and small reseller acquisitions to expand direct market presence.

Analysis

The cleanest read-through is that this is less a “beat” than a proof-of-concept that the model is becoming less cyclical in the places investors feared most. Weather and FX masked underlying traction, but the bigger signal is that operating leverage is now showing up even while they are still deliberately spending into sales capacity, IT, and product development. That matters because it suggests incremental revenue should translate more efficiently into EBITDA over the next 2-3 quarters once one-off ERP and transition costs fade.

The more interesting second-order effect is competitive, not financial. Management is effectively saying the biggest constraint is awareness and reimbursement friction, not demand or pricing, which implies the addressable market can expand faster than incumbents or new entrants can meaningfully take share. If they keep converting resellers to direct markets in Europe while maintaining U.S. reimbursement coverage, the company’s local-density advantage compounds: better field coverage improves prescription conversion, which improves payor relationships, which in turn lowers customer acquisition cost over time.

The setup is still vulnerable to narrative whiplash over the next 1-2 quarters. Investors may be underestimating how much of the current margin improvement is aided by timing, lower restructuring drag, and the normalization of temporary disruption rather than a permanently higher margin structure. The key risk is that the market prices the long-term 20% growth/15% EBIT margin target as already de-risked; if Q2 only looks “normal” instead of a sharp catch-up, the stock can de-rate despite the medium-term story remaining intact.

Contrarian view: the stock is probably not expensive if you believe the reimbursement machine scales, but consensus may be overpaying for near-term clean-up and underappreciating how lumpy quarterly conversion can remain. The right way to own it is not on a straight-line earnings comp, but on a 6-12 month view that the ERP transition, reseller conversions, and AI-enabled admin efficiency all converge into a step-up in cash conversion. If that doesn’t happen by late 2026, the multiple likely compresses because the market will conclude the growth story is still operationally managed, not structurally unlocked.

Key Decisions for Investors

• Long DYVOX on weakness over the next 1-2 weeks, using the post-print drift as entry: target a 10-15% move over 6-9 months if Q2 confirms deferred demand catch-up and ERP drag fades; stop if management signals that March was an isolated rebound rather than a normalized run-rate.
• Buy 3-6 month call spreads on DYVOX instead of outright equity to express upside from operating leverage while limiting downside if Q2 is merely average; structure for ~2:1 reward/risk around the next earnings date.
• Pair long DYVOX / short a higher-beta healthcare automation or small-cap growth name with weaker cash flow quality: DYVOX offers improving cash conversion plus visible reimbursement-led demand, while the short leg should underperform if the market rotates toward quality compounding.
• Take profits on any sharp post-earnings pop above the recent trading range; the stock can rerate only if management proves quarterly acceleration, so chasing after a strong print is lower expectancy than buying pullbacks.
• Monitor a 2Q inflection in Europe direct-market contribution and North American order normalization; if both show up, add to position into Q3 on the thesis that 2026 becomes a margin-recapture year, not just a growth year.